Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019049891) METHOD FOR TREATING CANCER BY COMBINATION OF Trk INHIBITOR AND KINASE INHIBITOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/049891 International Application No.: PCT/JP2018/032880
Publication Date: 14.03.2019 International Filing Date: 05.09.2018
IPC:
A61K 31/444 (2006.01) ,A61K 31/4184 (2006.01) ,A61K 31/506 (2006.01) ,A61K 31/519 (2006.01) ,A61K 45/00 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/02 (2006.01) ,A61P 43/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
444
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4184
condensed with carbocyclic rings, e.g. benzimidazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
Applicants:
小野薬品工業株式会社 ONO PHARMACEUTICAL CO., LTD. [JP/JP]; 大阪府大阪市中央区道修町2丁目1番5号 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 5418526, JP
Inventors:
小崎 龍平 KOZAKI, Ryohei; JP
加藤 光 KATO, Hikaru; JP
Agent:
特許業務法人三枝国際特許事務所 SAEGUSA & PARTNERS; 大阪府大阪市中央区道修町1-7-1 北浜TNKビル Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka 5410045, JP
Priority Data:
2017-17093606.09.2017JP
2017-17095006.09.2017JP
Title (EN) METHOD FOR TREATING CANCER BY COMBINATION OF Trk INHIBITOR AND KINASE INHIBITOR
(FR) MÉTHODE DE TRAITEMENT DU CANCER À L'AIDE D'UNE COMBINAISON D'INHIBITEUR DE Trk ET D'INHIBITEUR DE KINASES
(JA) Trk阻害剤とキナーゼ阻害剤の併用による癌治療方法
Abstract:
(EN) The present invention addresses the problem of providing a combination therapy by which an antitumor effect is enhanced in comparison to the case of administering a Trk inhibitor or various kinase inhibitors alone. According to the present invention, a Trk inhibitor, in particular, a compound represented by general formula (I) (in the formula, all symbols represent the same meaning as the symbols described in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is useful as an active ingredient of a cancer therapeutic agent used in combination with one or more drugs selected from the group consisting of an MEK inhibitor, a CDK4/6 inhibitor, an EGFR inhibitor and a JAK1/2 inhibitor.
(FR) La présente invention aborde le problème de la fourniture d'une polythérapie présentant un effet antitumoral amélioré par rapport à l'administration d'un inhibiteur de Trk ou de divers inhibiteurs de kinases seuls. Selon la présente invention, un inhibiteur de Trk, en particulier un composé représenté par la formule générale (I) (dans la formule, tous les symboles sont tels que définis dans la description), un sel de celui-ci, un N-oxyde de celui-ci, un solvate de celui-ci ou un promédicament de celui-ci, est utile en tant que principe actif d'un agent thérapeutique contre le cancer utilisé en combinaison avec un ou plusieurs médicaments choisis dans le groupe constitué par un inhibiteur de MEK, un inhibiteur de CDK4/6, un inhibiteur d'EGFR et un inhibiteur de JAK1/2.
(JA) 本発明の課題は、Trk阻害剤または各種キナーゼ阻害剤を単独で投与したときに比べて、抗腫瘍効果が増強される併用療法を提供することである。 Trk阻害剤、特に一般式(I)(式中、すべての記号は、明細書記載の記号と同じ意味を表す。)で示される化合物、その塩、それらのN-オキシド体、それらの溶媒和物、またはそれらのプロドラッグは、MEK阻害剤、CDK4/6阻害剤、EGFR阻害剤およびJAK1/2阻害剤からなる群から選択される一以上の薬物と併用して使用される癌治療剤の有効成分として有用である。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)